Scientists have found a mutation in Sars-Cov-2 that may help scientists to understand its neurological symptoms and the mystery of long Covid. With the help of the findings of the study, there is a possibility that they can treat the virus in the brain in the future.
The new collaborative study between scientists at Northwestern University and the University of Illinois-Chicago uncovered a series of mutations in the Sars-Cov-2 spike protein that enhanced the virus’ ability to infect the brains of mice.
(Source: Pixabay)
Chicago/USA – Scientists have discovered a mutation in Sars-Cov-2, the virus that causes Covid-19, that plays a key role in its ability to infect the central nervous system. The findings may help scientists understand its neurological symptoms and the mystery of “long Covid,” and they could one day even lead to specific treatments to protect and clear the virus from the brain.
The new collaborative study between scientists at Northwestern University and the University of Illinois-Chicago uncovered a series of mutations in the Sars-Cov-2 spike protein (the outer part of the virus that helps it penetrate cells) that enhanced the virus’ ability to infect the brains of mice.
“Looking at the genomes of viruses found in the brain compared to the lung, we found that viruses with a specific deletion in spike were much better at infecting the brains of these animals,” said co-corresponding author Judd Hultquist, assistant professor of medicine (infectious diseases) and microbiology-immunology at Northwestern University Feinberg School of Medicine. “This was completely unexpected, but very exciting.”
The study was published Aug. 23 in Nature Microbiology.
Changes in spike help the virus infect different cells in the body
In this study, researchers infected mice with Sars-Cov-2 and sequenced the genomes of viruses that replicated in the brain versus the lung. In the lung, the spike protein looked very similar to the virus used to infect the mice. In the brain, however, most viruses had a deletion or mutation in a critical region of spike that dictates how it enters a cell. When viruses with this deletion were used to directly infect the brains of mice, it was largely repaired when it traveled to the lungs.
“In order for the virus to traffic from the lung to the brain, it required changes in the spike protein that are already known to dictate how the virus gets into different types of cells,” Hultquist said. “We think this region of spike is a critical regulator of whether or not the virus gets into the brain, and it could have large implications for the treatment and management of neurological symptoms reported by Covid-19 patients.”
Sars-Cov-2 has long been associated with various neurological symptoms, such as the loss of smell and taste, “brain fog” and “long Covid.”
“It’s still not known if long Covid is caused by direct infection of cells in the brain or due to some adverse immune response that persists beyond the infection,” Hultquist said. “If it is caused by infection of cells in the central nervous system, our study suggests there may be specific treatments that could work better than others in clearing the virus from this compartment.”
The generation of new variants in the brain could produce new variants of concern in the population, said co-corresponding author Justin Richner, assistant professor of microbiology and immunology at UIC.
“It could be that the virus is using these different tissue sites to evolve into new, different variants, and then those can traffic back into the respiratory tract and then spread throughout the population,” Richner said. “Potentially this could be a source of novel variants of concern that emerge in the population.”
Other Northwestern authors on the study include Lacy M. Simons, Tanushree Dangi, Egon A. Ozer, Pablo Penaloza-MacMaster and Ramon Lorenzo-Redondo.
Funding for this study, “Evolution of Sars-Cov-2 in the murine central nervous system drives viral diversification,” was provided by the National Institutes of Health (grants R01AI150672; R56DE033249; R21AI163912 and U19AI135964); the Department of Defense (grant MS200290); and through institutional support for the Center for Pathogen Genomics and Microbial Evolution and the Northwestern University Clinical & Translational Sciences Institute (Nucats).
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.